![]() ![]() This cookie is set by GDPR Cookie Consent plugin. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement". You can set your browser to block or alert you about these cookies, but some parts of the site may not work. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. These cookies are necessary for the website to function and cannot be switched off in our systems. These cookies enable core functionality such as security, network management, and accessibility. Newark, CA: Revance Therapeutics, Inc, 2021. Carruthers JD, Fagien S, Joseph JH, et al. Bertucci V, Solish N, Kaufman-Janette J, et al. ![]() Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.ĭAXXIFY™ is not recommended for use in children or pregnant women.ġ. Use caution when administering to patients with pre-existing cardiovascular disease. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Recommended dose and frequency of administration should not be exceeded. The potency Units of DAXXIFY™ are not interchangeable with other preparations of other botulinum toxin products. Newark, CA: Revance Therapeutics, Inc, 2021.ĭAXXIFY™ (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. ![]() ![]() Carruthers JD, Fagien S, Joseph JH, et al.Bertucci V, Solish N, Kaufman-Janette J, et al. #CARLA ELITE AESTHETIC FULL#Please see DAXXIFY™ full Prescribing Information, including Boxed Warning and Medication Guide. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY™ is unknown.ĭAXXIFY ™ is not recommended for use in children or pregnant women. The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).Ĭo-administration of DAXXIFY™ and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY™ may be potentiated. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment. The potency Units of DAXXIFY ™ are not interchangeable with other preparations of other botulinum toxin products. Please refer to Boxed Warning for Distant Spread of Toxin Effect. INDICATIONDAXXIFY™ (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.ĭAXXIFY™ contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |